<DOC>
	<DOCNO>NCT02142192</DOCNO>
	<brief_summary>The primary objective study evaluate immunogenicity natalizumab ( BG00002 ) 300 mg subcutaneous ( SC ) administer participant relapse multiple sclerosis ( RMS ) . The secondary objective study evaluate safety natalizumab SC injection evaluate efficacy natalizumab SC injection relapse new magnetic resonance imaging ( MRI ) lesion .</brief_summary>
	<brief_title>Natalizumab Subcutaneous Immunogenicity Safety Study</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Natalizumab</mesh_term>
	<criteria>Key Must document diagnosis RMS screening . Must fall within therapeutic indication state locally approve label natalizumab . Must EDSS score 0 6.5 , inclusive . Key Any prior use natalizumab . Positive antinatalizumab antibody screen . Treatment immunomodulatory injection ( include IFNÎ² glatiramer acetate ) within 2 week prior Screening . NOTE : Other protocol define Inclusion/Exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>